CN106659766B - 烯醇酶1(eno1)组合物及其用途 - Google Patents

烯醇酶1(eno1)组合物及其用途 Download PDF

Info

Publication number
CN106659766B
CN106659766B CN201580012892.XA CN201580012892A CN106659766B CN 106659766 B CN106659766 B CN 106659766B CN 201580012892 A CN201580012892 A CN 201580012892A CN 106659766 B CN106659766 B CN 106659766B
Authority
CN
China
Prior art keywords
eno1
subject
dendrimer
pharmaceutical composition
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580012892.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN106659766A (zh
Inventor
N·R·纳莱恩
R·萨兰加拉詹
V·K·维施努达斯
S·吉斯塔
E·景
S·道纳特
S·K·德奥
J·J·吉梅内兹
E·迪克西
P·M·达夫塔里安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Berg Pharma LLC
Original Assignee
University of Miami
Berg Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami, Berg Pharma LLC filed Critical University of Miami
Publication of CN106659766A publication Critical patent/CN106659766A/zh
Application granted granted Critical
Publication of CN106659766B publication Critical patent/CN106659766B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
CN201580012892.XA 2014-01-13 2015-01-13 烯醇酶1(eno1)组合物及其用途 Active CN106659766B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461926913P 2014-01-13 2014-01-13
US61/926,913 2014-01-13
US201462009783P 2014-06-09 2014-06-09
US62/009,783 2014-06-09
US201562100881P 2015-01-07 2015-01-07
US62/100,881 2015-01-07
PCT/US2015/011276 WO2015106296A1 (en) 2014-01-13 2015-01-13 Enolse 1 (eno1) compositions and uses thereof

Publications (2)

Publication Number Publication Date
CN106659766A CN106659766A (zh) 2017-05-10
CN106659766B true CN106659766B (zh) 2025-03-28

Family

ID=53524434

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201580012892.XA Active CN106659766B (zh) 2014-01-13 2015-01-13 烯醇酶1(eno1)组合物及其用途
CN202011098097.6A Pending CN112336851A (zh) 2014-01-13 2015-01-13 烯醇酶1(eno1)组合物及其用途
CN201580012874.1A Expired - Fee Related CN106102835B (zh) 2014-01-13 2015-01-13 烯醇酶1(eno1)组合物及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202011098097.6A Pending CN112336851A (zh) 2014-01-13 2015-01-13 烯醇酶1(eno1)组合物及其用途
CN201580012874.1A Expired - Fee Related CN106102835B (zh) 2014-01-13 2015-01-13 烯醇酶1(eno1)组合物及其用途

Country Status (14)

Country Link
US (4) US10188708B2 (enExample)
EP (2) EP3094341B1 (enExample)
JP (2) JP6629234B2 (enExample)
KR (1) KR20160106175A (enExample)
CN (3) CN106659766B (enExample)
AU (2) AU2015204451A1 (enExample)
BR (1) BR112016016153A2 (enExample)
CA (2) CA2936691A1 (enExample)
EA (1) EA201691420A1 (enExample)
HK (1) HK1231425A1 (enExample)
IL (1) IL246720A0 (enExample)
MX (1) MX2016009102A (enExample)
SG (1) SG11201605698XA (enExample)
WO (2) WO2015106296A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659766B (zh) 2014-01-13 2025-03-28 博格有限责任公司 烯醇酶1(eno1)组合物及其用途
CN107847560A (zh) * 2015-06-22 2018-03-27 博格有限责任公司 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
US20200185063A1 (en) 2016-06-05 2020-06-11 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
CN107991493B (zh) * 2017-11-22 2020-03-31 中国医科大学附属第一医院 抗eno1自身抗体在对ait孕妇筛查和预测流产风险中的应用
CN112111462B (zh) * 2020-09-14 2022-08-23 兰州大学 烯醇化酶eno1单克隆抗体及其应用
KR20240099206A (ko) * 2021-11-26 2024-06-28 후닐라이프 바이오테크놀로지, 인코포레이트 인간 질병을 치료하기 위해 세포외 알파-에놀라제를 표적화하여 해당과정을 조절하는 방법
CN114533902A (zh) * 2022-02-28 2022-05-27 河南师范大学 一种过表达lrrc15基因的质粒载体及其制备方法和应用
CN115786317A (zh) * 2022-12-12 2023-03-14 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1720052A (zh) * 2002-12-06 2006-01-11 法布罗根股份有限公司 糖尿病等的治疗

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244576T1 (de) 1992-09-25 2003-07-15 Neorx Corp Therapeutischer inhibitor der vaskulären glatten muskelzellen
PL324091A1 (en) 1994-10-25 1998-05-11 Immulogic Pharma Corp Compositions and procedure for treating sclerosis multiplex
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US20030044795A1 (en) 1996-09-06 2003-03-06 Inger Byrajalsen Biochemical markers of the human endometrium
US7078375B1 (en) * 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
US6329501B1 (en) 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
WO2001016322A2 (en) 1999-09-01 2001-03-08 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2001016323A2 (en) 1999-09-01 2001-03-08 Subsidiary N0.3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
AU2470101A (en) 1999-10-25 2001-05-08 Affymetrix, Inc. Genetic sequences associated with neural cell proliferation and disease
CA2399058A1 (en) * 2000-02-02 2001-08-09 Transgene S.A. Targeting peptides
US20030203372A1 (en) 2000-12-08 2003-10-30 Ward Neil Raymond Analysis method
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
US20040058326A1 (en) 2001-07-27 2004-03-25 Brooksbank Robert Alan Identification and use of molecules implicated in pain
US20050191627A1 (en) 2001-09-28 2005-09-01 Incyte Corporation Enzymes
WO2003064501A1 (en) 2002-01-31 2003-08-07 Clarke Slemon Conformationally restricted compounds as dendrimer cores
US20050222023A1 (en) 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
JP2004081111A (ja) * 2002-08-27 2004-03-18 Yamaguchi Technology Licensing Organization Ltd 虚血性心疾患の治療薬として新規活性を有するα−エノラーゼおよびその利用法
CA2503748A1 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2004055519A2 (en) 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
AU2003300178A1 (en) 2002-12-30 2004-07-29 Ppd Development, Lp Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2004084950A2 (en) 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005073621A (ja) 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
CA2540529C (en) 2003-10-03 2012-03-13 Vib Vzw Means and methods for the recruitment and identification of stem cells
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
EP1664775A4 (en) 2004-07-06 2008-03-12 Kuhnil Pharm Co Ltd COMPOSITION FOR THE DIAGNOSIS OF RETINAL VASCULAR DISEASE COMPRISING ALDOLASE AND DIAGNOSTIC METHOD USING THE SAME
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
EP1843781B1 (en) 2005-01-03 2015-03-18 Jeon, Sook-yeong Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
EP2121747A2 (en) 2006-07-27 2009-11-25 Oxford Genome Sciences (UK) Limited New protein isoforms and uses thereof
US8071721B2 (en) 2006-09-29 2011-12-06 Ribovax Biotechnologies S.A. Antigens and antibodies associated to pancreatic ductal adenocarcinoma
US20100047256A1 (en) 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
EP2155177A2 (en) 2007-04-30 2010-02-24 Intezyne Technologies Incorporated Modification of biological targeting groups for the treatment of cancer
AU2008273096B2 (en) 2007-07-12 2013-05-02 Academisch Ziekenhuis Leiden Molecules for targeting compounds to various selected organs or tissues
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
JP5429707B2 (ja) 2008-03-27 2014-02-26 国立大学法人群馬大学 微粒子およびその製造方法
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
DK2315532T3 (da) 2008-07-18 2014-10-20 Hills Pet Nutrition Inc Sammensætninger og fremgangsmåder til behandling af forstyrrelser, der er associeret med overvægtige dyr
EP2194382A1 (en) 2008-12-03 2010-06-09 Universität des Saarlandes An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
WO2011064552A1 (en) 2009-11-30 2011-06-03 Isis Innovation Limited Conjugates for delivery of biologically active compounds
WO2011072290A2 (en) * 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
MX2012013735A (es) 2010-05-28 2013-04-29 Mind Nrg Sa Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US20140086895A1 (en) 2011-05-10 2014-03-27 Universite De Rouen Methods and pharmaceutical compositions for the treatment of autoimmune diseases
GB201113814D0 (en) 2011-08-10 2011-09-28 Proteome Sciences R & D Gmbh & Co Kg Materials and methods for determining sensitivity potential of compounds
CN103998458B (zh) 2011-08-30 2018-10-09 医学研究理事会 具有中央疏水域的细胞穿透肽
CN104144707B (zh) 2011-12-14 2018-09-14 得克萨斯系统大学董事会 用于癌症疗法的连带基因失活生物标志和靶标
EP2877214B1 (en) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
CA2889693C (en) 2012-10-30 2021-07-13 Particle Sciences, Inc. Drug delivery particle formulations with targeting moieties
CN106659766B (zh) 2014-01-13 2025-03-28 博格有限责任公司 烯醇酶1(eno1)组合物及其用途
CN107847560A (zh) 2015-06-22 2018-03-27 博格有限责任公司 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途
CA2992611A1 (en) 2015-07-16 2017-01-19 Berg Llc Enolase 1 (eno1) compositions and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1720052A (zh) * 2002-12-06 2006-01-11 法布罗根股份有限公司 糖尿病等的治疗

Also Published As

Publication number Publication date
CA2936691A1 (en) 2015-07-16
CN106659766A (zh) 2017-05-10
AU2015204452A1 (en) 2016-08-11
EA201691420A1 (ru) 2016-12-30
WO2015106295A2 (en) 2015-07-16
HK1231425A1 (zh) 2017-12-22
BR112016016153A2 (pt) 2017-12-12
KR20160106175A (ko) 2016-09-09
JP6629234B2 (ja) 2020-01-15
AU2015204451A1 (en) 2016-07-28
SG11201605698XA (en) 2016-08-30
JP2017508000A (ja) 2017-03-23
US10188708B2 (en) 2019-01-29
US20190307863A1 (en) 2019-10-10
HK1231394A1 (en) 2017-12-22
JP6644006B2 (ja) 2020-02-12
EP3094379A2 (en) 2016-11-23
CN106102835B (zh) 2020-11-03
US11224641B2 (en) 2022-01-18
CN112336851A (zh) 2021-02-09
US20150361409A1 (en) 2015-12-17
CN106102835A (zh) 2016-11-09
US10188707B2 (en) 2019-01-29
EP3094379A4 (en) 2017-06-28
JP2017509690A (ja) 2017-04-06
WO2015106296A8 (en) 2015-08-20
EP3094341A4 (en) 2017-11-01
WO2015106296A1 (en) 2015-07-16
EP3094341B1 (en) 2019-10-02
CA2936694A1 (en) 2015-07-16
MX2016009102A (es) 2016-09-09
US20150359861A1 (en) 2015-12-17
EP3094341A1 (en) 2016-11-23
IL246720A0 (en) 2016-08-31
WO2015106295A3 (en) 2015-11-05
US20190307864A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
CN106659766B (zh) 烯醇酶1(eno1)组合物及其用途
US20200150131A1 (en) Diagnostic advanced glycation end-product antibodies
US12188950B2 (en) Blood biomarkers and diagnostic methods for small vessel diseases
AU2014366827A1 (en) Method of diagnosis and treatment
JP2019506374A (ja) メトホルミンのバイオマーカーとしての増殖分化因子１５
JP2024037767A (ja) 改変型線維芽細胞成長因子２１（ｆｇｆ－２１）を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の処置方法
CA3158285A1 (en) Theranostics for hypertension induced myocardial microbleeds
EP3645736A1 (en) Method for determining the risk to develop type 1 diabetes
JP5739433B2 (ja) 血中インスリン抵抗性及び糖尿病マーカープログラニュリン、採血試料中のプログラニュリン濃度の分析方法、及び、インスリン抵抗性を改善及び糖尿病を改善又は抑制する物質のスクリーニング方法
US20120329046A1 (en) Molecular marker for evaluating pathological conditions and treatment of muscular dystrophy
HK1231394B (en) Enolase 1 (eno1) compositions and uses thereof
JP2006503265A (ja) 糖尿病およびインスリン抵抗性の診断および治療の方法
CN119546635A (zh) 新颖的可溶性尿激酶纤溶酶原激活物受体(suPAR)结合分子及其用途
MXPA06014924A (es) Procedimientos para predecir la respuesta terapeutica frente a agentes que actuan en el receptor de la hormona del crecimiento.
JP2008502909A (ja) 糖尿病およびインスリン抵抗性の診断および治療の方法
WO2014113519A1 (en) Using galectin-binding carbohydrates as predictors of melanoma progression and metastasis
JP2012085603A (ja) 微小血管障害又はその関連疾患のバイオマーカー

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant